Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
- PMID: 32726529
- PMCID: PMC7299433
- DOI: 10.1056/NEJMoa1908380
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
Abstract
Background: Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants.
Methods: Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season, were randomly assigned in an overall ratio of approximately 2:1 to receive a single intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo. Infants were followed for 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess safety. The primary end point was RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and the primary analysis of vaccine efficacy against the primary end point was performed in the per-protocol population of infants (prespecified criterion for success, lower bound of the 97.52% confidence interval [CI] of ≥30%).
Results: A total of 4636 women underwent randomization, and there were 4579 live births. During the first 90 days of life, the percentage of infants with RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine group and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, -1.0 to 63.7; 95% CI, 5.3 to 61.2). The corresponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 95% CI, -8.2 to 75.3), and the percentages for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5). Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups.
Conclusions: RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life. The suggestion of a possible benefit with respect to other end-point events involving RSV-associated respiratory disease in infants warrants further study. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov NCT02624947.).
Copyright © 2020 Massachusetts Medical Society.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7299433/bin/NEJM-2020-1908380-g001.gif)
![Figure 2 a-c](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7299433/bin/NEJM-2020-1908380-g002.gif)
Comment in
-
Disarming the Respiratory Syncytial Virus.N Engl J Med. 2020 Jul 30;383(5):487-488. doi: 10.1056/NEJMe2021648. N Engl J Med. 2020. PMID: 32726536 No abstract available.
-
Respiratory syncytial virus vaccination in pregnancy is not effective enough at reducing infant infections.Arch Dis Child Educ Pract Ed. 2022 Oct;107(5):389. doi: 10.1136/archdischild-2020-321368. Epub 2021 Mar 3. Arch Dis Child Educ Pract Ed. 2022. PMID: 33658293 No abstract available.
Similar articles
-
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. N Engl J Med. 2023. PMID: 37018474 Clinical Trial.
-
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. N Engl J Med. 2020. PMID: 32726528 Clinical Trial.
-
RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478. N Engl J Med. 2024. PMID: 38477988 Clinical Trial.
-
Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.Expert Rev Vaccines. 2021 Apr;20(4):351-364. doi: 10.1080/14760584.2021.1903877. Epub 2021 May 2. Expert Rev Vaccines. 2021. PMID: 33733995 Review.
-
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?Curr Opin Infect Dis. 2015 Jun;28(3):221-4. doi: 10.1097/QCO.0000000000000161. Curr Opin Infect Dis. 2015. PMID: 25918956 Review.
Cited by
-
Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure.Front Immunol. 2024 Apr 30;15:1377374. doi: 10.3389/fimmu.2024.1377374. eCollection 2024. Front Immunol. 2024. PMID: 38745662 Free PMC article.
-
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Cochrane Database Syst Rev. 2024. PMID: 38695784 Review.
-
Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland.Immun Inflamm Dis. 2024 Apr;12(4):e1257. doi: 10.1002/iid3.1257. Immun Inflamm Dis. 2024. PMID: 38661110 Free PMC article.
-
Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.Vaccine X. 2024 Feb 23;18:100464. doi: 10.1016/j.jvacx.2024.100464. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38495929 Free PMC article. Review.
-
Respiratory Syncytial Virus, Influenza and SARS-CoV-2 in Homeless People from Urban Shelters: A Systematic Review and Meta-Analysis (2023).Epidemiologia (Basel). 2024 Jan 31;5(1):41-79. doi: 10.3390/epidemiologia5010004. Epidemiologia (Basel). 2024. PMID: 38390917 Free PMC article. Review.
References
-
- Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec 2015;90:433-58. - PubMed
-
- Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012;87:461-76. - PubMed
-
- Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec 2017;92:53-76. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical